盐酸齐拉西酮胶囊治疗首发精神分裂症80例临床研究

摘要

目的：比较盐酸齐拉西酮胶囊对首发精神分裂症患者的疗效；方法选择80例首发精神分裂症患者，分为治疗组和对照组，在各时间点选择症状量表和临床疗效总评量表为评价指标，进行统计学分析。结果盐酸齐拉西酮胶囊组和奥氮平组的PANSS和CGI-S评分有效率有显著性差异（P＜0.05）。结论两种药物对首发精神分裂症患者均具有较好的疗效，并且证明盐酸齐拉西酮胶囊疗效更佳。%ObjectiveTo compare the efifcacy of Ziprasidone hydrochloride capsules in the treatment of ifrst-episode schizophrenic patients,Methods Eighty first-episode schizophrenia patients were randomly assigned to treatment group and control group, The Positive and Negative Syndrome Scale and the Clinical Global Impression-severity scale were used to assess the efficacy at each point in times. Statisticalanalysis of the indicators in each group. Results The changes of the total score of PANSS and CGI-SII were different between the two groups. Ziprasidone hydrochloride capsules could induce more extrapyramidal side effects than olanzapine (P <0.05). Conclution Ziprasidone hydrochloride capsules and olanzapine could use to treat first-episode schizophrenia safely with the efficacy. But results proved that the efficacy of ziprasidone hydrochloride capsules was better.